Navigation Links
Can personalized tumor vaccines improve interleukin-2 treated metastatic melanoma?
Date:1/22/2014

New Rochelle, NY, January 22, 2014Metastatic melanoma has a poor prognosis, but treatment with high-dose interleukin-2 (IL2) can extend survival. Now, a combination of IL2 therapy and activation of patients' immune systems using personalized vaccines made from their own tumor cells has been shown to improve survival rates even more than IL2 alone, according to a new article in Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Cancer Biotherapy and Radiopharmaceuticals website.

"High-Dose IL2 in Metastatic Melanoma: Better Survival in Patients Immunized with Antigens from Autologous Tumor Cell Lines" describes a statistically significant improvement in survival for patients who received IL2 plus tumor cell-based immunotherapy. Authors Robert Dillman, Carol DePriest and Stephanie McClure, Hoag Institute for Research and Education, Hoag Family Cancer Institute, and Cancer Biotherapy Research Group, Newport Beach, CA, found that administration of immunotherapy after IL2 treatment resulted in longer patient survival than if individuals were vaccinated before receiving IL2.

"This is an important addition to the literature on IL2 treatment for metastatic melanoma demonstrating that personalized vaccine therapy contributed to an increased survival rate," says Co-Editor-in-Chief Donald J. Buchsbaum, PhD, Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham.


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2156
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Page: 1

Related biology news :

1. How can we improve the efficacy of antipsychotics in the era of personalized pharmacotherapy?
2. A cost-effective way toward personalized cancer drugs
3. Oncogenic signatures mapped in TCGA a guide for the development of personalized therapy
4. "GenoVive is changing the face of personalized health by continuing research efforts with Harvard."
5. Cancer research implies future for personalized medicine, reduction in animal testing
6. Notre Dame researchers develop system that uses a big data approach to personalized healthcare
7. Frost & Sullivan Applauds geneOnyx for its DNA Testing Solution for the Personalized Cosmeceuticals Market
8. Personalized health care will revolutionize 21st century medicine, says NJIT professor
9. Personalized medicine eliminates need for drug in 2 children
10. Report from the front lines of personalized reproductive medicine revolution
11. BodyMedia & FitOrbit Up the Ante in Personalized Weight Loss
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Can personalized tumor vaccines improve interleukin-2 treated metastatic melanoma?
(Date:8/14/2019)... ... August 14, 2019 , ... Join Jonathan Riek, PhD, ... on Tuesday, September 10, 2019 at 1pm EDT to learn about two common ... management. , NAFLD is the most common diffuse liver disease, with a worldwide ...
(Date:8/14/2019)... Calif. (PRWEB) , ... August 13, 2019 , ... Dr. Julie Reck of Veterinary ... to her patients. Her first stem cell patient, her own geriatric Australian Shepherd, ... According to Dr. Reck, Simon wanted to play but his body was weak, and he ...
(Date:8/6/2019)... ... August 05, 2019 , ... Keck Graduate Institute (KGI) President Sheldon Schuster ... Health Sciences (SPHS). , “Dean Zdanowicz is highly regarded as an innovative leader who ... “He is a great choice to build on the success of the KGI School ...
Breaking Biology News(10 mins):
(Date:7/23/2019)... ... 2019 , ... While today Visikol is primarily focused on ... 3D tissue imaging , digital pathology , 3D cell culture models ... a products company. These products are focused on addressing the limitations associated with ...
(Date:7/19/2019)... ... July 18, 2019 , ... World renowned two-time Everest summiter ... with California-based charity Coalition Duchenne for its 9th Annual Expedition Mt. Kinabalu in ... funding for Duchenne muscular dystrophy and was founded by Sabahan Catherine Jayasuriya. ...
(Date:7/17/2019)... ... July 16, 2019 , ... ... agreement for the development and manufacturing of Zolgensma® (onasemnogene abeparvovec-xioi), an AveXis ... AveXis, a Novartis company, will have dedicated manufacturing space at the new, ...
(Date:7/11/2019)... ... ... At the most recent stem cell training course in Las ... R3 Heroes Program. The Veterans included individuals and families from all over the US, ... a military Veteran, teacher or first responder to receive a regenerative therapy at a ...
Breaking Biology Technology: